Hiroyuki Abe to Receptor, ErbB-2
This is a "connection" page, showing publications Hiroyuki Abe has written about Receptor, ErbB-2.
Connection Strength
1.616
-
Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan. Gastric Cancer. 2025 Mar; 28(2):294-300.
Score: 0.772
-
MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes. J Magn Reson Imaging. 2015 Oct; 42(4):920-4.
Score: 0.392
-
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 12; 104:9-15.
Score: 0.176
-
Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology. 2021 Feb; 78(3):381-391.
Score: 0.144
-
Intratumoral heterogeneity of the distribution of kinetic parameters in breast cancer: comparison based on the molecular subtypes of invasive breast cancer. Breast Cancer. 2015 Sep; 22(5):496-502.
Score: 0.091
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 11; 196(1):57-66.
Score: 0.041